| Bayer AG NA (DE000BAY0017) | |||
26,46 EURStand (close): 01.07.25 |
 |
||
Nachrichten |
||
| Datum / Uhrzeit | Titel | Bewertung |
| 27.06.25 13:50:00 | Biopesticides Industry Research and Forecast Report 2021-2031 with Competitive Analysis of Corteva, Syngenta, BASF, Bayer, Koppert Biological Systems, |  |
| Company Logo The Global Biopesticides Market is projected to grow at a CAGR of 11.72%, reaching USD 19.67 Billion by 2031, driven by rising demand for eco-friendly farming. Key trends include integrated pest management and biotech innovations. This comprehensive report covers market segmentation, regional analysis, and major players like UPL Ltd, Corteva Inc., and Syngenta. Dublin, June 27, 2025 (GLOBE NEWSWIRE) -- The "Biopesticides Market (2025 Edition): Analysis By Type (Bioinsecticide, Biofungicide, Bionematicide, and Others), By Crop Type, By Mode of Application: Market Insights and Forecast (2021-2031)" report has been added to ResearchAndMarkets.com's offering. The Global Biopesticides market showcased growth at a CAGR of 11.72% during 2021-2024. The market was valued at USD 7.98 Billion in 2024 which is expected to reach USD 19.67 Billion in 2031. This report provides a complete analysis for the historical period of 2021-2024, the estimates of 2025 and the forecast period of 2026-2031. The global biopesticides market is experiencing significant growth, driven by multiple factors that highlight the increasing demand for eco-friendly and sustainable agricultural practices. One of the primary driving forces behind this expansion is the growing awareness among consumers about the harmful effects of chemical pesticides on human health, wildlife, and the environment. As conventional pesticides have been linked to various health issues, environmental damage, and the development of resistant pest populations, farmers and consumers are increasingly turning to biopesticides as a safer alternative. The growing global demand for organic food is a significant factor driving the biopesticides market. As consumers become more health-conscious and demand food that is free from synthetic chemicals, organic farming practices are expanding worldwide. Organic certification bodies and regulations are also promoting the use of biopesticides to protect crops from pests and diseases. Furthermore, many government policies worldwide are aligning with this shift, encouraging the use of biopesticides by offering subsidies and financial incentives for their adoption, while also introducing stringent regulations that limit the use of harmful chemical pesticides. These regulations have created a favorable environment for the growth of biopesticides, making them a crucial component of modern agricultural practices. One of the prominent trends in the biopesticides market is the increasing adoption of integrated pest management (IPM) strategies, which combine various pest control methods, including biological control, chemical control, and cultural practices, to reduce the reliance on chemical pesticides. Biopesticides play a vital role in IPM systems by providing a natural, less harmful alternative to traditional chemicals. Story Continues The trend towards IPM is being driven by the need for more sustainable farming practices and by the growing recognition that the overuse of chemical pesticides can lead to issues such as pesticide resistance, environmental contamination, and harm to non-target species. Biopesticides, when used within an IPM framework, can help mitigate these risks by providing a more sustainable and environmentally friendly pest control option. This trend is particularly prominent in regions with high agricultural output, such as North America and Europe, where the focus on sustainability and environmental protection is a priority. Technological advancements have also played a significant role in driving the biopesticides market. Biotechnological innovations, such as genetic engineering, microbial fermentation, and synthetic biology, have enabled the production of more effective and efficient biopesticides. Through these advancements, biopesticides have been engineered to enhance their effectiveness, targeting specific pests and diseases with greater precision. Additionally, they have been optimized for longer shelf life, stability, and resistance to environmental conditions, which traditionally limited their application and marketability. For instance, genetically modified microorganisms, such as bacteria and fungi, have been developed to produce biopesticides that are highly efficient in combating a wide range of agricultural pests while minimizing harm to beneficial organisms like pollinators. Such advancements are making biopesticides more viable and appealing to farmers seeking pest control solutions that are both effective and safe for the environment. Furthermore, the development of biopesticides that can target specific pests while leaving beneficial organisms unharmed is a key area of technological innovation. For example, biopesticides that specifically target insect pests without affecting pollinators such as bees or natural predators like ladybugs are becoming more common. This specificity not only makes biopesticides more effective but also reduces their impact on biodiversity, helping to maintain ecosystem balance. The development of these highly specific biopesticides is a crucial step in ensuring that they can be integrated into modern farming systems without disrupting the delicate balance of the ecosystem. In conclusion, the global biopesticides market is being driven by a combination of environmental, regulatory, technological, and consumer-driven factors. As sustainability becomes a central focus for both farmers and consumers, the market for biopesticides is expected to continue growing, with advancements in biotechnology and application technologies further enhancing their effectiveness. While regions like North America and Europe are already seeing significant growth, Asia Pacific and the Middle East and Africa present promising opportunities for the future. The ongoing development of biopesticides that are highly targeted, environmentally friendly, and economically viable will be key to the continued success of this market. Scope of the Report The report analyses the Biopesticides Market by Value (USD Million). The report analyses the Biopesticides Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Brazil, France, Germany, Italy, Spain, China, Japan, and India). The report presents the analysis of Biopesticides Market for the historical period of 2021-2024, the estimated year 2025 and the forecast period of 2026-2031. The report analyses the Biopesticides Market by Type (Bioinsecticide, Biofungicide, Bionematicide, and Others). The report analyses the Biopesticides Market by Crop Type (Fruits & Vegetables, Cereals & Grains, Oilseeds & Pulses, and Others). The report analyses the Biopesticides Market by Mode of Application (Foliar Spray, Soil Treatment, Seed Treatment, and Others). The key insights of the report have been presented through the frameworks of SWOT. Also, the attractiveness of the market has been presented by region, by type, by crop type, & by mode of application. Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report. The report tracks competitive developments, strategies, mergers and acquisitions and new product development. Analyst Recommendations Leverage the shift toward integrated pest management (IPM) Expand into high-growth emerging markets Competitive Positioning:Companies' Product Positioning, Market Share Analysis of Biopesticides Market, Company ProfilesUPL Ltd Corteva Inc Syngenta BASF Bayer Koppert Biological Systems Certis Biologicals For more information about this report visit https://www.researchandmarkets.com/r/h7zqfs About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 View Comments |
||
| 25.06.25 14:00:00 | EY US & Bayer Win “Artificial Intelligence for Good” Award in 2025 AI Breakthrough Awards Program |  |
| AI Breakthrough Prestigious International Annual Awards Program Honors Standout AI Companies & Solutions LOS ANGELES, June 25, 2025 (GLOBE NEWSWIRE) -- AI Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global Artificial Intelligence (AI) market, today announced that Ernst & Young LLP (EY US) and the Crop Science division of Bayer, have been selected as the winner of the “AI for Good Award” in the 8th annual AI Breakthrough Awards program. EY US in collaboration with Bayer developed a breakthrough GenAI solution called E.L.Y. to bring greater speed and accuracy to how Bayer's frontline employees deliver crucial agronomic knowledge to farmers. With its industry-leading repository of specialized agronomic and product information for farmers, Bayer partnered with EY to build a system capable of understanding and responding to complex, natural language queries that agronomic advisors receive from farmer customers. With plans underway for global expansion, including in developing nations, the solution has been fully implemented by thousands of Bayer employees in the U.S. The breakthrough solution has been trained on a large language model (LLM) built on the Microsoft Azure AI Foundry using decades of Bayer's aggregated agronomy content, Azure OpenAI Service, Azure Data Manager and Azure AI Search with the lates GPT-series models and proprietary insights. The resulting system achieves outstanding accuracy in its response based on the algorithms used to format information from different sources into digestible data that further informs the GenAI system. Offerings consist of a vast array of seeds and traits, crop protection products, and digital solutions for agriculture. Retrieval Augmented Generation (RAG) dynamically retrieves relevant information to respond, in real-time, to prompt inquiries. Prompt engineering further tailors the system’s responses to help ensure accuracy on applied agronomy questions. “At EY, we believe that proof, not promises, is what gives our clients the confidence to boldly transform -- to take on not only their challenges, but some of the biggest issues facing society today,” said Whitt Butler, EY Americas Vice Chair, Consulting. “Our work with Bayer demonstrates how GenAI can be responsibly scaled to solve real-world issues—accelerating access to agronomic expertise, empowering advisors, and ultimately helping farmers make more informed decisions to increase the global food supply. It’s innovation with purpose, and we’re proud to be part of it.” Story Continues "Being named one of the 2025 ‘AI for Good’ winners is a proud moment for all of us and a direct reflection of the incredible work by our team to drive more on-farm value for our customers," said Brian Naber, President of North America & Australia/New Zealand Region at Bayer's Crop Science division. "Our U.S. customer-facing teams are the first to welcome E.L.Y. – our GenAI powered agronomic agent – as a virtual agronomy partner to help them deliver faster, more informed and personalized support. This innovation is helping us deliver an unparalleled customer experience—one that’s rooted in trust, responsiveness, and a deep understanding of customers’ needs." The AI Breakthrough Awards shine a spotlight on the boldest innovators and most impactful technologies leading the charge in AI across a comprehensive set of categories, including Generative AI, Computer Vision, AIOps, Agentic AI, Robotics, Natural Language Processing, industry-specific AI applications and many more. This year’s program attracted more than 5,000 nominations from over 20 different countries throughout the world, underscoring the explosive growth and global importance of AI as a defining technology of the 21st century. “GenAI is planting the seeds of the future and addressing the critical challenge of global food security,” said Steve Johansson, managing director, AI Breakthrough. “By making critical agronomic knowledge readily accessible, GenAI can empower those responsible for feeding the world, contributing significantly to a more food-secure and resilient global future. We’re pleased to recognize EY US and Bayer Crop Science for this incredible AI-driven contribution to the global good.” About AI Breakthrough Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the AI Breakthrough Awards program is devoted to honoring excellence in Artificial Intelligence technologies, services, companies and products. The AI Breakthrough Awards provide public recognition for the achievements of AI companies and products in categories including Generative AI, Machine Learning, AI Platforms, Robotics, Business Intelligence, AI Hardware, Computer Vision and more. For more information visit AIBreakthroughAwards.com. Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose. About EY EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets. Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow. EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions. Fueled by sector insights, a globally connected, multi-disciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories. All in to shape the future with confidence. EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com. CONTACT: Media Contact: Steve Johansson 213.255.3658 steve@aibreakthroughawards.com View Comments |
||
| 23.06.25 14:17:53 | Exelixis Surges On Positive Results For Next-Gen Colon Cancer Drug |  |
| Exelixis stock surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study. Continue Reading View Comments |
||
| 23.06.25 13:53:00 | FDA Extends INCY's Application for Opzelura Label Expansion | |
| Incyte INCY announced that the FDA has extended the review period for the supplemental new drug application (sNDA) for ruxolitinib cream. The sNDA is seeking approval of the cream for the treatment of children 2-11 years old with mild to moderate atopic dermatitis (AD), a chronic immune-mediated skin condition. High Yield Savings Offers Earn 4.10% APY** on balances of $5,000 or more View Offer Earn up to 4.00% APY with Savings Pods View Offer Earn up to 3.80% APY¹ & up to $300 Cash Bonus with Direct Deposit View Offer Powered by Money.com - Yahoo may earn commission from the links above. The target action date has been extended by three months to Sept. 19, 2025, to provide FDA with the time to review additional chemistry, manufacturing and controls (CMC) data on the 0.75% strength submitted by Incyte in response to a recent information request by the regulatory body. Year to date, shares of Incyte have lost 0.9% compared with the industry’s decline of 2.5%.Zacks Investment Research Image Source: Zacks Investment Research More on INCY’s Opzelura Ruxolitinib cream is a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib. It is approved by the FDA under the brand name Opzelura for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older. The sNDA was based on data from the phase III TRuE-AD3 study, which evaluated the safety and efficacy of ruxolitinib cream in children (age ≥2 to <12 years) with AD. This study met its primary endpoint with significantly more patients treated with Opzelura, achieving Investigator’s Global Assessment-treatment success (IGA-TS) — a measure of treatment efficacy — than with vehicle control (non-medicated cream). In addition, a secondary endpoint of patients demonstrating at least a 75% improvement in the Eczema Area and Severity Index (EASI75) at Week 8 was achieved. Please note that Opzelura is already approved in the United States for the topical short-term and non-continuous chronic treatment of mild to moderate AD in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. First-quarter net revenues from Opzelura cream were $119 million, up +38%. Incyte Corporation Price, Consensus and EPS Surprise Incyte Corporation price-consensus-eps-surprise-chart | Incyte Corporation Quote INCY’s Efforts to Diversify Portfolio Incyte is looking to expand its portfolio and reduce dependence on lead drug Jakafi (ruxolitinib). Jakafi is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older. Story Continues Sales in all indications continue to be strong and should maintain momentum going forward. The approval of Opzelura has been a significant boost for the company. Other drugs like Pemazyre and newly approved drugs like Monjuvi and Tabrecta have helped INCY’s cause to diversify its portfolio. Earlier this month, the FDA approved the label expansion of Monjuvi in combination with Rituxan (rituximab) and Revlimid (lenalidomide) for the treatment of adult patients with relapsed or refractory follicular lymphoma, a type of slow-growing blood cancer. Last month, the FDA approved Zynyz (retifanlimab-dlwr), a PD-1 inhibitor, in combination with platinum-based chemotherapy (carboplatin and paclitaxel) for the first-line treatment of adult patients with locally recurrent or metastatic squamous cell carcinoma of the anal canal. Although the uptake of recently approved drugs has been good and a potential approval of the additional drugs should diversify its portfolio, INCY is heavily dependent on Jakafi for its top-line growth. Moreover, competition has increased for some of Jakafi’s approved indications with the FDA’s approval of GSK plc’s GSK Ojjaara for the treatment of intermediate or high-risk MF, including primary MF or secondary MF (post-polycythemia vera and post-essential thrombocythaemia), in adults with anemia. GSK posted strong growth in Ojjaara sales for the first quarter of 2025 (£112 million), driven by continued uptake in the United States and contributions from Europe and International regions. Jakafi is also expected to lose patent protection in a few years. INCY’s Zacks Rank and Stocks to Consider Incyte currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Immunocore IMCR and Bayer BAYRY. While IMCR sports a Zacks Rank #1 (Strong Buy) at present, Bayer carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Immunocore In the past 60 days, loss per share estimates for Immunocore’s 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained 6.3% year to date. Immunocore’s earnings beat estimates in three of the trailing four quarters and missed the mark once, delivering an average surprise of 76.18%. Bayer BAYRY’s 2025 earnings per share estimate has increased from $1.19 to $1.25 for 2025 over the past 60 days, while that for 2026 has gone up from $1.28 to $1.31 over the same timeframe. Year to date, shares of Bayer have surged 57.9%. BAYRY’s earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report Incyte Corporation (INCY) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 23.06.25 13:36:44 | Exelixis Catapults 14% On Positive Results For Next-Gen Colon Cancer Drug | |
| Exelixis stock surged Monday after the company said its next-generation cancer drug showed promise in a colon cancer study. Continue Reading View Comments |
||
| 18.06.25 14:51:00 | Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane | |
| Bayer BAYRY announced that it has submitted a new drug application (“NDA”) to the FDA seeking approval for its investigational low-dose gadolinium-based contrast agent (“GBCA”), gadoquatrane, for use in contrast-enhanced magnetic resonance imaging (“MRI”) of the central nervous system and other body regions for adults and pediatric patients, including term neonates. High Yield Savings Offers Earn 4.10% APY** on balances of $5,000 or more View Offer Earn up to 4.00% APY with Savings Pods View Offer Earn up to 3.80% APY¹ & up to $300 Cash Bonus with Direct Deposit View Offer Powered by Money.com - Yahoo may earn commission from the links above. The proposed dose of 0.04 mmol gadolinium per kilogram (Gd/kg) represents a substantial reduction, approximately 60%, compared to the current standard of care, which is macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight. Earlier this month, Bayer submitted a marketing authorization application to Japan’s Ministry of Health, Labour and Welfare (“MHLW”) for gadoquatrane. The MRI contrast agent is intended to enhance imaging of suspected or known conditions across all body regions in both adults and pediatric patients, including neonates. Year to date, shares of Bayer have rallied 58% compared with the industry’s rise of 2.6%.Zacks Investment Research Image Source: Zacks Investment Research Potential Nod to Gadoquatrane to Expand BAYRY's Portfolio The NDA submission was based on positive data from the pivotal phase III QUANTI studies, which evaluated the safety and efficacy of gadoquatrane in adult and pediatric patients worldwide. The QUANTI study confirmed that gadoquatrane effectively met both its primary and secondary efficacy endpoints in improving image quality and helping identify lesions during scans. These results support its potential as a reliable contrast agent for accurate diagnosis. Also, data from the QUANTI Pediatric study, which is part of the QUANTI studies, showed that gadoquatrane behaves the same way in children as it does in adults. It was also found to be generally safe for both age groups, with no new safety concerns reported. The need for medical imaging is growing, mainly because more people are getting chronic diseases like cancer and heart problems. If approved, gadoquatrane would become the lowest-dose macrocyclic GBCA to be available in the United States, further strengthening Bayer’s leadership in the field of radiology. BAYRY's Zacks Rank & Other Stocks to Consider Bayer currently carries a Zacks Rank #2 (Buy). Some other top-ranked stocks in the biotech sector are Exelixis EXEL, Amarin Corporation AMRN and Puma Biotechnology PBYI each carrying a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for Exelixis’ earnings per share have increased from $2.31 to $2.61 for 2025. During the same time, earnings per share estimates for 2026 have increased from $2.83 to $3.03. Year to date, shares of EXEL have increased 24.2%. Story Continues EXEL’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 48.60%. In the past 60 days, estimates for Amarin’s loss per share have narrowed from $5.00 to $2.50 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $3.87 to $1.78. Year to date, shares of AMRN have surged 38.3%. AMRN’s earnings beat estimates in two of the trailing four quarters, met the same once and missed the same on the remaining occasion, the average surprise being 29.11%. In the past 60 days, estimates for Puma Biotechnology’s earnings per share have increased from 60 cents to 65 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from 46 cents to 51 cents. Year to date, shares of PBYI have risen 12.5%. PBYI’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 171.43%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report Exelixis, Inc. (EXEL) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report Puma Biotechnology, Inc. (PBYI) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 17.06.25 15:00:00 | Bayer Files for Approval of gadoquatrane in the U.S. | |
| FDA submission seeks approval for investigational gadolinium-based contrast agent (GBCA) gadoquatrane for contrast-enhanced magnetic resonance imaging (MRI) of the central nervous system (CNS) and other body regions for adults and pediatric patients including term neonates Submitted dose corresponds to a 60 percent reduction in gadolinium compared to macrocyclic GBCAs dosed at 0.1 mmol gadolinium per kilogram of body weight Not intended for mediaoutside of the US WHIPPANY, N.J., June 17, 2025--(BUSINESS WIRE)--Bayer today announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for its investigational contrast agent gadoquatrane for contrast-enhanced magnetic resonance imaging of the CNS and other body regions in adults and pediatric patients including term neonates. The submitted dose is 0.04 mmol gadolinium per kilogram body weight. If approved, gadoquatrane would become the lowest dose macrocyclic GBCA available in the U.S., corresponding to a 60 percent reduction compared to macrocyclic GBCAs dosed at 0.1 mmol Gd/kg body weight. The submission of gadoquatrane to the US FDA is based on positive data from the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane in adult and pediatric patients globally. The first results from the Phase III QUANTI CNS study were presented at the European Congress of Radiology (ECR) in February of this year and further results are planned to be presented at upcoming scientific meetings. Nearly 40 million MRI scans are performed each year in the United States. "There is a rising need for medical imaging, among others driven by the increasing incidence of chronic diseases such as cancer and cardiovascular diseases," said Dr. Konstanze Diefenbach, Head of Radiology Research & Development, Bayer. "As a leader in radiology, we are committed to advancing innovation in this field, including options to reduce the gadolinium dose. Patients can benefit from a dose reduction, especially patients with chronic conditions who require multiple contrast-enhanced MRI examinations during their lifetime. This is in line with guidance from health authorities and guidelines from scientific bodies which recommend using the lowest dose required to obtain the needed clinical information." Bayer recently announced the submission of gadoquatrane to the Ministry of Health, Labour, and Welfare (MHLW) in Japan, marking the first application for marketing authorization for the investigational contrast agent. Further regulatory applications to health authorities worldwide are planned for the coming months. Story Continues About the Phase III development program QUANTI The pivotal QUANTI clinical development program investigated gadoquatrane at a dose of 0.04 mmol Gd/kg body weight, which represents a 60 percent lower gadolinium dose compared to macrocyclic contrast agents dosed at 0.1 mmol Gd/kg body weight. QUANTI consisted of two large multinational, randomized, prospective double-blind, crossover Phase III studies – QUANTI CNS (Central Nervous System) and QUANTI OBR (Other Body Regions) – as well as the QUANTI Pediatric study. In total, 808 patients in 15 countries participated in the program. The QUANTI study results show that gadoquatrane met the primary and secondary efficacy endpoints of the studies assessing visualization parameters and lesion detection. Results of QUANTI Pediatric demonstrated that the pharmacokinetic behavior of gadoquatrane in children is similar to that in adults. The observed safety profile in adults as well as pediatric patients from birth to < 18 years of age in the QUANTI studies was generally consistent with previous data on gadoquatrane and other macrocyclic GBCAs. No new safety signals were observed. About gadoquatrane Gadoquatrane is Bayer’s investigational extracellular macrocyclic contrast agent in clinical development for contrast enhancement in MRI. This low dose gadolinium-based contrast agent features a distinct tetrameric structure with high stability and high relaxivity. About MRI With an estimated 65 million procedures performed annually worldwide, contrast-enhanced MRI plays a key role in the healthcare continuum. MRI is a non-invasive, radiation-free imaging method that provides detailed images of the body, helping to identify and distinguish potential abnormalities in organs and tissues. This supports physicians in answering critical medical questions related to the detection and monitoring of diseases. About Radiology at Bayer Building on a century of expertise, Bayer is committed to innovative products and high-quality services in diagnostic imaging to enhance patient care. Its leading radiology portfolio features contrast agents and devices for precise administration across modalities including computed tomography (CT), X-ray and magnetic resonance imaging (MRI), and positron emission tomography (PET). Bayer’s comprehensive offerings also include informatics solutions and a medical imaging platform with digital and artificial intelligence (AI) powered applications. In 2024, Bayer’s radiology products generated €2.1 billion in sales. Bayer continues to advance research and innovation in medical imaging, including the integration of AI. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. View source version on businesswire.com: https://www.businesswire.com/news/home/20250616347143/en/ Contacts Contact for media inquiries: Victoria Vigener, phone +49 151 23438911 Email: victoria.vigener@bayer.com Contact for US media inquiries: Jennifer May, phone, 412-656-8192 Email: jennifer.may@bayer.com Find more information at www.bayer.com. View Comments |
||
| 16.06.25 13:06:00 | 5 Large Drug Stocks That Are Poised to Ride on Sector Recovery | |
| The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries hurt global stock markets in April. With the massive tariffs imposed by the United States and China currently on a pause, the markets recovered slightly. However, this is only a temporary suspension. The uncertainty around tariffs and trade production measures remains, which has muted economic growth. However, amid the broader macro uncertainty, the drug and biotech sector seems to have recovered in the past month, backed by positive pipeline and regulatory developments. Innovation is at its peak with key spaces like rare diseases, next-generation oncology treatments, obesity, immunology and neuroscience attracting investor attention. M&A activity also remains healthy. Regular pipeline setbacks, slow ramp-up of newer drugs, patent cliffs, regulatory risks and broader market concerns related to the economy are some of the headwinds for the sector. Nonetheless, large drugmakers have several robust revenue streams and are mostly profitable companies, making them safe havens for investments. Among the large drugmakers, AbbVie ABBV, Novartis NVS, Pfizer PFE, Sanofi SNY and Bayer BAYRY are worth retaining in one’s portfolio. Advertisement: High Yield Savings Offers Earn 4.10% APY** on balances of $5,000 or more View Offer Earn up to 4.00% APY with Savings Pods View Offer Earn up to 3.80% APY¹ & up to $300 Cash Bonus with Direct Deposit View Offer Powered by Money.com - Yahoo may earn commission from the links above. Industry Description The Zacks Large Cap Pharmaceuticals industry comprises some of the largest global companies that develop multi-million-dollar drugs for a broad range of therapeutic areas, like neuroscience, cardiovascular and metabolism, rare diseases, immunology and oncology. Some of these companies also make vaccines, animal health products, medical devices and consumer-related healthcare products. They invest millions of dollars in their product pipelines and line extensions of their already-marketed drugs. Continuous innovation is a defining characteristic of pharma companies, and these large drugmakers are constantly investing in drug development and the discovery of new medicines. Regular mergers and acquisitions, and collaboration deals are other key features of large drugmakers. What's Shaping the Future of the Large-Cap Pharma Industry? Innovation and Pipeline Success: For big drugmakers, an innovative pipeline is a competitive necessity and key to top-line growth. Pharma companies are continually striving to ramp up innovation and allocate a significant portion of their revenues to R&D. Several drugmakers are embracing AI technology to accelerate the drug discovery process for delivering more effective therapies. Successful innovation and product line extensions in key therapeutic areas, along with strong clinical study results, may serve as important catalysts for these stocks. Story Continues Aggressive M&A & Collaboration Activity: The sector is characterized by aggressive M&A activities. Given that it takes several years and millions of dollars to develop new therapeutics from scratch, large pharmaceutical companies, sitting on substantial cash reserves, regularly acquire innovative small and mid-cap biotech companies to expand their pipelines. Also, sloppy sales of mature drugs, dwindling in-house pipelines, government scrutiny of drug prices and the growing use of AI for drug discovery whet the M&A appetite of large drugmakers. Moreover, collaborations and partnerships with smaller companies are in full swing. Fast-growing and lucrative markets such as oncology, rare disease and cell and gene therapy are likely to remain focus areas for M&A activities. Recently, areas such as obesity and inflammatory bowel disease have been attracting buyout interest. An important M&A deal announced recently was Sanofi’s offer to acquire Blueprint Medicines for approximately $9.5 billion. M&A activity is expected to remain rampant through the rest of the year. Pipeline Setbacks & Other Headwinds: The failure of key pipeline candidates in pivotal studies and regulatory and pipeline delays can be setbacks for large drug companies and significantly hurt their share prices. Other headwinds for the industry include pricing and competitive pressure, generic competition for blockbuster treatments, a slowdown in sales of some of the most high-profile older drugs, Medicare drug price negotiations and increasing FTC scrutiny of M&A deals. Macroeconomic Uncertainty: Uncertain macroeconomic conditions, including the risk of inflation, fluctuating interest rates and instability in the financial system, along with escalating geopolitical tensions in various parts of the world, have increased broader economic woes. Uncertainties around tariffs also remain a headwind. Zacks Industry Rank Indicates a Bright Outlook The Zacks Large Cap Pharmaceuticals industry is an 11-stock group within the broader Medical sector. The group’s Zacks Industry Rank is basically the average of the Zacks Rank of all the member stocks. The Zacks Large Cap Pharmaceuticals industry currently carries a Zacks Industry Rank #36, which places it in the top 15% of 245 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Before we present a few large drug stocks that are well-positioned to outperform the market based on a strong earnings outlook, let’s take a look at the industry’s performance and its current valuation. Industry Versus S&P 500 & Sector The industry has outpaced the Zacks Medical Sector as well as the S&P 500 year to date. Stocks in this industry have collectively risen 3.9% so far this year against the Zacks Medical Sector’s decline of 1.5%. The Zacks S&P 500 composite has risen 1.7%. YTD Price Performance Industry's Current Valuation Based on the forward 12-month price-to-earnings (P/E), a commonly used multiple for valuing large pharma companies, the industry is currently trading at 15.65X compared with the S&P 500’s 21.89X and the Zacks Medical Sector's 19.31X. Over the last five years, the industry has traded as high as 20.80X, as low as 12.92X and at a median of 15.65X, as the chart below shows. Forward 12-Month Price-to-Earnings (P/E) Ratio 5 Large Drugmakers to Watch Bayer: The company’s key drugs, Nubeqa for cancer and Kerendia for chronic kidney disease associated with type II diabetes, are fueling growth in its Pharmaceuticals division. Bayer is also working to expand the labels of Nubeqa and Kerendia, which, if successful, can further drive growth. The company also plans to launch two new drugs in 2025, which are elinzanetant, a hormone-free treatment for menopause symptoms, and ceramides, a drug for the treatment of a certain form of heart disease. The Consumer Health segment also improved in 2024 due to the launch of new products, which should keep the momentum in 2025. However, sales in the Crop Science division declined significantly in the past couple of years due to lower volumes and prices for glyphosate-based products. This Zacks Rank #2 (Buy) company’s shares have risen 61.9% so far this year. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Estimates for its 2025 earnings per share have increased from $1.19 to $1.25 over the past 60 days. Price and Consensus: BAYRY Pfizer: It is one of the largest and most successful drugmakers in the field of oncology. The company’s position in oncology was strengthened with the addition of Seagen in 2023. Though COVID revenues are declining, its non-COVID operational revenues are improving, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen. Pfizer faces its share of challenges, the key being declining sales of its COVID-19 products. It also expects a significant impact from the loss of patent exclusivity in the 2026-2030 period, as several of its key products may face patent expirations. The Medicare Part D redesign under the Inflation Reduction Act (IRA) is also expected to negatively impact sales of Pfizer’s higher-priced drugs, such as Vyndaqel, Ibrance, Xtandi and Xeljanz,in 2025. However, as COVID-related uncertainties dwindle, its revenue volatility is also declining. The company’s non-COVID drugs and contribution from new and newly acquired products should continue to drive top-line growth in 2025. Also, Pfizer expects cost cuts and internal restructuring to deliver savings of at least $6.0 billion. Continued growth in non-COVID sales and significant cost-reduction measures should drive profit growth. Pfizer has a Zacks Rank #2 at present. The Zacks Consensus Estimate for 2025 EPS has risen from $2.98to $3.06 per share over the past 60 days. The stock has lost 4.2% year to date. Price and Consensus: PFE Novartis: With the separation of Sandoz, Novartis has become a pure-play pharmaceutical company. Novartis maintains strong momentum on the back of a strong and diverse portfolio with drugs like Kisqali, Kesimpta, Pluvicto and Leqvio. The uptake of Pluvicto and Scemblix has been outstanding and should propel top-line growth. Approval of new drugs and label expansion of existing drugs should enable Novartis to offset the adverse impacts of the generic competition of key drugs. Novartis is also looking to solidify its presence in the promising gene therapy space. The recent spate of acquisitions and collaborations has strengthened its pipeline. However, generic erosion of some drugs and recent pipeline setbacks are a concern. Novartis has a Zacks Rank #2 at present. The Zacks Consensus Estimate for this Swiss drugmaker’s 2025 EPS has risen from $8.46 to $8.74 over the past 60 days. The stock has risen 25.6% so far this year. Price and Consensus: NVS AbbVie: It has successfully navigated the loss of exclusivity (LOE) of its blockbuster drug, Humira, by launching two other successful new immunology medicines, Skyrizi and Rinvoq, which are performing extremely well, bolstered by approvals in new indications and should support top-line growth in the next few years. AbbVie expects to return to robust revenue growth in 2025, which is just the second year following the U.S. Humira LOE, driven by its ex-Humira platform. Boosted by its new product launches, AbbVie expects to return to robust mid-single-digit revenue growth in 2025 with a high single-digit CAGR through 2029, as it has no significant LOE event for the rest of this decade. Strong sales performance of drugs like Rinvoq, Skyrizi, Venclexta and Vraylar, coupled with significant contributions from newer drugs like Ubrelvy, Elahere, Epkinly and Qulipta, should keep driving the company’s top line. AbbVie has several early/mid-stage pipeline candidates with blockbuster potential. The company expects several regulatory submissions, approvals and key data readouts in the next 12 months. The company has been on an acquisition spree in the past couple of years, which is strengthening its pipeline. AbbVie has a Zacks Rank #3 (Hold) at present. The stock has risen 9.5% year to date. The Zacks Consensus Estimate for 2025 earnings has remained stable at $12.28 per share over the past 60 days. Price and Consensus: ABBV Sanofi: Dupixent has become the key top-line driver for Sanofi as it enjoys strong demand across all approved indications and geographies. New uses, increased penetration in approved indications and further geographic expansion are expected to drive Dupixent’s sales in future quarters. Sanofi possesses a leading vaccine portfolio, which drives the top line. Several new drugs were launched in the past couple of years that have become significant contributors to Sanofi's accelerated top-line growth profile. Sanofi increased R&D investments and achieved significant progress with its pipeline in 2024. It has also been active on the M&A front. However, generic erosion of Aubagio in all key markets and lower sales from mature products are hurting sales. Other headwinds include the weak sales of influenza vaccines and regular negative pipeline developments. Sanofi has a Zacks Rank #3 at present. The stock has risen 6.3% year to date. The Zacks Consensus Estimate for 2025 EPS has risen from $4.43 to $4.56 over the past 60 days. Price and Consensus: SNY Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AbbVie Inc. (ABBV) : Free Stock Analysis Report Sanofi (SNY) : Free Stock Analysis Report Novartis AG (NVS) : Free Stock Analysis Report Pfizer Inc. (PFE) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 13.06.25 13:40:11 | Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? | |
| The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Amneal Pharmaceuticals (AMRX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question. Amneal Pharmaceuticals is one of 998 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Amneal Pharmaceuticals is currently sporting a Zacks Rank of #2 (Buy). The Zacks Consensus Estimate for AMRX's full-year earnings has moved 5% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving. Based on the latest available data, AMRX has gained about 0.5% so far this year. At the same time, Medical stocks have lost an average of 1.5%. This means that Amneal Pharmaceuticals is performing better than its sector in terms of year-to-date returns. One other Medical stock that has outperformed the sector so far this year is Bayer Aktiengesellschaft (BAYRY). The stock is up 64.6% year-to-date. In Bayer Aktiengesellschaft's case, the consensus EPS estimate for the current year increased 3.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy). Looking more specifically, Amneal Pharmaceuticals belongs to the Medical - Drugs industry, which includes 164 individual stocks and currently sits at #73 in the Zacks Industry Rank. Stocks in this group have gained about 4.4% so far this year, so AMRX is slightly underperforming its industry this group in terms of year-to-date returns. Bayer Aktiengesellschaft, however, belongs to the Large Cap Pharmaceuticals industry. Currently, this 11-stock industry is ranked #38. The industry has moved +2.8% so far this year. Investors with an interest in Medical stocks should continue to track Amneal Pharmaceuticals and Bayer Aktiengesellschaft. These stocks will be looking to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Story Continues AMNEAL PHARMACEUTICALS, INC. (AMRX) : Free Stock Analysis Report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 06.06.25 03:25:28 | Goldman Sachs Upgrades Bayer (BAYRY) to Buy | |
| On Thursday, Goldman Sachs analyst James Quigley upgraded Bayer Aktiengesellschaft (OTC:BAYRY) to Buy from Neutral, while setting a price target of EUR 33. Quigley indicated that the stock's risk/reward profile appears positive as it approaches H2 2025, with potential catalysts that could drive a re-rating in the medium term.Goldman Sachs Upgrades Bayer (BAYRY) to Buy, Sets a EUR 33 PT A closeup of pills in a pharmacy, representing the high quality medications of the company. This upgrade follows Bayer's strong operational start to the year, characterized by cost discipline in its Crop Science division and robust momentum in its underlying Pharmaceuticals business. Goldman Sachs suggests that these factors indicate Bayer may have reached the bottom of its negative earnings revision cycle. In key business developments, Bayer's EPS stood at EUR 2.49 in Q1 2025, keeping the company on track to achieve EUR 4.50 to 5.00 at constant currencies for the full year. While sales in the company's Crop Science division declined by 3% due to regulatory impacts affecting higher-margin sales, the Pharmaceuticals segment sales grew by 4% due to an 80% year-over-year increase in Nubeqa and Kerendia sales. Nubeqa is a prostate cancer drug, while Kerendia is used to treat chronic kidney disease associated with type 2 diabetes. The Consumer Health segment sales also increased by 2.5%. Bayer Aktiengesellschaft (OTC:BAYRY) is a global life science company. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. While we acknowledge the potential of BAYRY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Related Content OTC View Comments |
||
